(Q35625795)

9 August 2017

1 reference

title

An update of the etiology and management of xerostomia (English)

1 reference

9 August 2017

2

Scully C

1 reference

9 August 2017

Porter SR

1

1 reference

PubMed ID

14716254

9 August 2017

Hegarty AM

series ordinal

3

1 reference

9 August 2017

1 January 2004

1 reference

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

9 August 2017

1 reference

9 August 2017

97

1 reference

9 August 2017

1

1 reference

9 August 2017

28-46

1 reference

Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The salivary glands. Embryology, anatomy, and surgical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Adverse drug reactions in the mouth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

7 January 2021

Omeprazole and dry mouth

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Effects of antihypertensive medications on quality of life in elderly hypertensive women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Hydrallazine-induced Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral health care for the cancer patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral complications of cancer therapies: prevention and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Xerostomia in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Histopathological study of the human submandibular gland in graft versus host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral manifestations of chronic graft-v-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Update in Sjögren syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Classification criteria for Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Current issues in Sjögren's syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Association of Sjögren's syndrome with HLA-B8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Sicca syndrome in patients with sarcoidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

HIV: the surgeon's perspective. Part 3. Diagnosis and management of malignant neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

HIV-associated salivary gland disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Synergism between HIV and other viruses in the mouth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

HIV topic update: protease inhibitor therapy and oral health care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Orofacial effects of antiretroviral therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Xerostomia associated with didanosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Hepatitis C virus infection: Review and implications for the dentist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Serum levels of gamma-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Hepatitis C virus in saliva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Whole stimulated salivary flow in patients with chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral health of patients with hepatitis C virus infection: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison of Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Immunohistochemistry of minor salivary gland biopsy specimens from patients with Sjögren's syndrome with and without hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Epstein-Barr virus as an etiological agent in primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

High prevalence of Sjögren's syndrome in patients with HTLV-I associated myelopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Chronic infection with hepatitis and herpes viruses in patients with Sjogren's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The flow rate and composition of human labial gland saliva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Parotid salivary secretion in diabetic autonomic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Studies of dental and oral changes of pregnant diabetic women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

What the mouth has to say about diabetes. Careful examinations can avert serious complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Alteration in parotid salivary flow in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Xerostomia in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Saliva in non-insulin-dependent diabetic patients and control subjects: The role of the autonomic nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Impaired salivary function in patients with noninsulin-dependent diabetes mellitus with xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Salivary gland involvement in hypohidrotic ectodermal dysplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Xerostomia in patients with triple A syndrome--a newly recognised finding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Sicca syndrome with iron deposition in the salivary glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Sicca symptom in a patient with hemochromatosis: minor salivary gland biopsy for differential diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Sjögren's syndrome as seen by an oral physician.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The oral side of Sjögren syndrome. Diagnosis and treatment. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Saliva substitutes: how effective and safe are they?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Treatment of xerostomia following radiotherapy: does age matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Hyperthermic, supersaturated humidification in the treatment of xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Patient preferences in a preliminary study comparing an intra-oral lubricating device with the usual dry mouth lubricating methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine as an antagonist to the undesired effects of ganglion-blocking agents in the treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

PILOCARPINE NITRATE AND PSYCHOSTIMULANTS. ANTAGONISTIC AGENT TO ANTICHOLINERGIC EFFECTS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Preemptive pharmacologic intervention in radiation-induced salivary dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Amifostine in clinical oncology: current use and future applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine and carbacholine in treatment of radiation-induced xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Effectiveness of pilocarpine in postradiation xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Prevention and treatment of the consequences of head and neck radiotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine for radiation-induced xerostomia in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Radiation-induced hyposalivation and its treatment with oral pilocarpine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The use of oral pilocarpine in xerostomia and Sjögren's syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

s-IgA and cytokine levels in whole saliva of Sjögren's syndrome patients before and after oral pilocarpine hydrochloride administration: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pilocarpine for anticholinergic adverse effects associated with desipramine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Fluoride and pilocarpine reduce the risk of caries produced by chronic clomipramine treatment in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The use of bethanechol chloride with tricyclic antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Use of bethanechol chloride with phenothiazines: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

(+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pharmacotherapy of xerostomia in primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Enhancement of phosphatidylinositol turnover and cyclic nucleotide accumulation by chronic anethole trithione treatment in rat submaxillary glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Enhancement of salivary secretion and neuropeptide (substance P, alpha-calcitonin gene-related peptide) levels in saliva by chronic anethole trithione treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Synergistic effect of sialagogues in management of xerostomia after radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Lacrimal and salivary secretion in Sjögren's syndrome: the effect of systemic treatment with bromhexine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. A placebo controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The effect of acupuncture on salivary flow rates in patients with xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Acupuncture treatment of patients with radiation-induced xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Patients with primary Sjögren's syndrome treated for two months with evening primrose oil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Evening primrose oil and borage oil in rheumatologic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

A preliminary study on the interferon-alpha treatment for xerostomia of Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Oral prednisolone improved acetylcholine-induced sweating in Sjögren's syndrome-related anhidrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Treatment of primary Sjögren's syndrome with hydroxychloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Respiratory function in systemic lupus erythematosus: relation with activity and severity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Antimalarial ocular toxicity a critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Sjögren's syndrome: current therapies remain inadequate for a common disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Potential novel uses of thalidomide: focus on palliative care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Zidovudine in primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

Use of orally administered anhydrous crystalline maltose for relief of dry mouth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

RETRACTED: Infliximab in primary Sjögren's syndrome: one-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

The treatment of Sjögren's syndrome patients with pilocarpine-tablets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2003.07.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRIPLEO.2003.07.010

1 reference

9 August 2017

1 reference

PubMed ID

14716254